Photodynamic Therapy in Treating Patients With Lung Cancer

Inclusion Criteria:

Patients with biopsy confirmed carcinoma-in-situ (CIS) or microinvasive lung cancer
Patients may have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma
Patients may have received prior therapy for lung cancer of any type, e.g. chemotherapy, radiation therapy
Patients must have no contraindications for bronchoscopy
Female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal
Patients must have a Karnofsky scale 50 or above (Eastern Cooperative Oncology Group [ECOG] 0-2)
Patients must sign an Informed Consent according to Food and Drug Administration (FDA) guidelines acceptable to the Roswell Park Cancer Institute (RPCI) Institutional Review Board (IRB)
Patients with underlying lung disease must be judged (by the principal investigator) able to with stand mucous/debris formation at the site of treatment
Definition of CIS or microinvasive lung cancer for this protocol: the lesion will be radiographically occult and not definable by conventional computed tomography (CT) of the chest; the lesion may or may not be invisible on white light bronchoscopy, but is definable and photographable on lung imaging fluorescence endoscope (LIFE) bronchoscopy; biopsies of the lesion must indicate no evidence of invasion beyond cartilage on histopathology; the lesion may, however, be invasive through the basement membrane (microinvasive carcinoma)

Exclusion Criteria:

Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds
White blood cells (WBC) < 4000
Platelet count < 100,000
Prothrombin time exceeding 1.5 times the upper normal limit
Total serum bilirubin > 3.0 mg/dl
Serum creatinine > 3.0 mg/dl
Alkaline phosphatase (hepatic) or serum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper normal limit
Severe chronic obstructive pulmonary disease (COPD) that would in the opinion of the investigator preclude multiple bronchoscopies or partial central airway obstruction from mucous/debris formation
Any evidence of worsening pulmonary symptoms or COPD exacerbation
Evidence of major pulmonary vessel encasement on CT scan of the chest
Myocardial infarction (Ml) or unstable angina in the previous 6 months